What is INVOKANA®? | INVOKANA® (canagliflozin)
In adults with type 2 diabetes and diabetic kidney disease
Lower the risks of end-stage kidney disease and hospitalization for heart failure
INVOKANA® is the only type 2 diabetes medicine proven to lower the risk of end-stage kidney disease (ESKD), worsening of kidney function, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes and diabetic kidney disease (nephropathy) with a certain amount of protein in the urine.
In adults with type 2 diabetes and established cardiovascular disease
Lower the risk of major cardiovascular events
INVOKANA® has been proven to lower the risk of heart attack, stroke, and cardiovascular death.
In adults with type 2 diabetes
INVOKANA® along with diet and exercise, has been proven to lower blood sugar (A1C). In most clinical studies, INVOKANA® helped a majority of people reach the ADA-recommended A1C goal of <7%.
Most common side effects
The most common side effects of INVOKANA® include genital yeast infections, urinary tract infections, and changes in urination.